Her-2-neu expression and progression toward androgen independence in human prostate cancer - PubMed (original) (raw)
. 2000 Dec 6;92(23):1918-25.
doi: 10.1093/jnci/92.23.1918.
R Montironi, J Manola, A Altimari, C Tam, G Bubley, S Balk, G Thomas, I Kaplan, L Hlatky, P Hahnfeldt, P Kantoff, M Loda
Affiliations
- PMID: 11106683
- DOI: 10.1093/jnci/92.23.1918
Her-2-neu expression and progression toward androgen independence in human prostate cancer
S Signoretti et al. J Natl Cancer Inst. 2000.
Abstract
Background: Human prostate cancers are initially androgen dependent but ultimately become androgen independent. Overexpression of the Her-2-neu receptor tyrosine kinase has been associated with the progression to androgen independence in prostate cancer cells. We examined the expression of Her-2-neu in normal and cancerous prostate tissues to assess its role in the progression to androgen independence.
Methods: Prostate cancer tissue sections were obtained from 67 patients treated by surgery alone (UNT tumors), 34 patients treated with total androgen ablation therapy before surgery (TAA tumors), and 18 patients in whom total androgen ablation therapy failed and who developed bone metastases (androgen-independent [AI] disease). The sections were immunostained for Her-2-neu, androgen receptor (AR), prostate-specific antigen (PSA), and Ki-67 (a marker of cell proliferation) protein expression. Messenger RNA (mRNA) levels and gene amplification of Her-2-neu were examined by RNA in situ hybridization and fluorescent in situ hybridization(FISH), respectively, in a subset of 27 tumors (nine UNT, 11 TAA, and seven AI). All statistical tests were two-sided.
Results: Her-2-neu protein expression was statistically significantly higher in TAA tumors than in UNT tumors with the use of two different scoring methods (P =.008 and P =.002). The proportion of Her-2-neu-positive tumors increased from the UNT group (17 of 67) to the TAA group (20 of 34) to the AI group (14 of 18) (P<.001). When compared with UNT tumors, tumor cell proliferation was higher in AI tumors (P =.014) and lower in TAA tumors (P<.001). All tumors expressed AR and PSA proteins. Although Her-2-neu mRNA expression was high in TAA and AI tumors, no Her-2-neu gene amplification was detected by FISH in any of the tumor types.
Conclusions: Her-2-neu expression appears to increase with progression to androgen independence. Thus, therapeutic targeting of this tyrosine kinase in prostate cancer may be warranted.
Comment in
- HER2 in prostate cancer--a viable target or innocent bystander?
Scher HI. Scher HI. J Natl Cancer Inst. 2000 Dec 6;92(23):1866-8. doi: 10.1093/jnci/92.23.1866. J Natl Cancer Inst. 2000. PMID: 11106669 Review. No abstract available.
Similar articles
- Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
Shi Y, Chatterjee SJ, Brands FH, Shi SR, Pootrakul L, Taylor CR, Datar R, Cote RJ. Shi Y, et al. BJU Int. 2006 Jan;97(1):170-8. doi: 10.1111/j.1464-410X.2006.05857.x. BJU Int. 2006. PMID: 16336351 - Human epidermal receptor-2 expression in prostate cancer.
Calvo BF, Levine AM, Marcos M, Collins QF, Iacocca MV, Caskey LS, Gregory CW, Lin Y, Whang YE, Earp HS, Mohler JL. Calvo BF, et al. Clin Cancer Res. 2003 Mar;9(3):1087-97. Clin Cancer Res. 2003. PMID: 12631612 - HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization.
Ross JS, Sheehan C, Hayner-Buchan AM, Ambros RA, Kallakury BV, Kaufman R, Fisher HA, Muraca PJ. Ross JS, et al. Hum Pathol. 1997 Jul;28(7):827-33. doi: 10.1016/s0046-8177(97)90157-x. Hum Pathol. 1997. PMID: 9224752 - HER-2/neu receptor in prostate cancer development and progression to androgen independence.
Di Lorenzo G, Autorino R, De Laurentiis M, Cindolo L, D'Armiento M, Bianco AR, De Placido S. Di Lorenzo G, et al. Tumori. 2004 Mar-Apr;90(2):163-70. doi: 10.1177/030089160409000201. Tumori. 2004. PMID: 15237576 Review. - Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer.
Veeramani S, Yuan TC, Chen SJ, Lin FF, Petersen JE, Shaheduzzaman S, Srivastava S, MacDonald RG, Lin MF. Veeramani S, et al. Endocr Relat Cancer. 2005 Dec;12(4):805-22. doi: 10.1677/erc.1.00950. Endocr Relat Cancer. 2005. PMID: 16322323 Review.
Cited by
- Pleiotropic effects of p300-mediated acetylation on p68 and p72 RNA helicase.
Mooney SM, Goel A, D'Assoro AB, Salisbury JL, Janknecht R. Mooney SM, et al. J Biol Chem. 2010 Oct 1;285(40):30443-52. doi: 10.1074/jbc.M110.143792. Epub 2010 Jul 27. J Biol Chem. 2010. PMID: 20663877 Free PMC article. - CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer.
Zhang P, Wang J, Gao W, Yuan BZ, Rogers J, Reed E. Zhang P, et al. Mol Cancer. 2004 May 4;3:14. doi: 10.1186/1476-4598-3-14. Mol Cancer. 2004. PMID: 15125777 Free PMC article. - Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes.
Pinthus JH, Waks T, Malina V, Kaufman-Francis K, Harmelin A, Aizenberg I, Kanety H, Ramon J, Eshhar Z. Pinthus JH, et al. J Clin Invest. 2004 Dec;114(12):1774-81. doi: 10.1172/JCI22284. J Clin Invest. 2004. PMID: 15599402 Free PMC article. - Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer.
Lyons LS, Rao S, Balkan W, Faysal J, Maiorino CA, Burnstein KL. Lyons LS, et al. Mol Endocrinol. 2008 Mar;22(3):597-608. doi: 10.1210/me.2007-0158. Epub 2007 Dec 13. Mol Endocrinol. 2008. PMID: 18079321 Free PMC article. - Basic science of hormonal therapy for prostate cancer.
Peehl DM. Peehl DM. Rev Urol. 2001;3 Suppl 3(Suppl 3):S15-22. Rev Urol. 2001. PMID: 16986004 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous